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PEMBANGUNAN PERPUSTAKAAN FAB ANTIBODI NAIF MANUSIA 
UNTUK MENGHASILKAN ANTIBODI MONOKLONAL TERHADAP 
ANTIGEN REKOMBINAN BmSXP 
ABSTRAK 
Antibodi adalah glykoprotein yang dihasilkan oleh sel B terhadap jasad molekul 
asing. Penyelidikan ini bertujuan menghasilkan antibodi Fab (fragmen ikatan 
antigen) manusia yang specifik terhadap antigen. Fragmen Fab terbahagi kepada satu 
domain malar dan domain manipulasi yang terletak pada rantai berat dan rantai 
ringan. Protokol optimum telah dicapai bagi menghasilkan perpustakaan Fab 
antibodi rekombinan daripada  penderma tidak berimunisasi yang terdiri daripada 
tiga kumpulan etnik majoriti (Melayu, Cina dan India) di Malaysia. Kami 
menggunakan seluruh RNA dari limfosit periferal darah daripada 90 penderma bagi 
mendapatkan gen-gen manipulasi cDNA yang spesifik. Fragmen antibodi Fab yang 
mengekod bagi kelas IgM diamplifikasi secara individu melalui proses PCR 
menggunakan kepelbagaian set-set primer yang merujuk kepada bahagian manipulasi 
rantai berat (µ) dan rantai ringan (κ,λ). Kepelbagaian perpustakaan antibodi dicapai 
melalui gabungan-gabungan campuran semua rantai berat dan rantai ringan secara 
rawak. Kepelbagian perpustakaan antibodi naif yang tinggi adalah sangat berguna 
untuk saringan antibodi terhadap beberapa panel antigen. Saringan faj dilakukan 
terhadap antigen BmSXP meggunakan dua strategi ‗panning‘ yang berbeza untuk 
memahami keberkesanan strategi ‗panning‘. BmSXP adalah antigen rekombinan bagi 
Wuchereria Bancrofti yang spesifik untuk penyakit limfatik Bancroftian filaria dan ia 
digunakan untuk kegunaan diagnostik bagi jangkitan limfatik filaria. Persembahan 
kedua-dua strategi ‗panning‘ menunjukkan kesukaran ‗panning‘ perpustakaan Fab 
secara proses automatik manakala cara ‗panning‘ konvensional berjaya 
xx 
  
mengasingkan gabungan-gabungan positif. Dua Fab antibodi monoklonal terhadap 
antigen BmSXP telah dikesan dan disahkan. Walaupun penghasilan perpustakaan 
Fab naif  adalah sukar, namun ia berguna untuk penghasilan Fab antibodi 
monoklonal untuk aplikasi-aplikasi hiliran seperti diagnostik. ‗Panning‘ 
perpustakaan Fab naif secara paparan faj boleh menghasilkan antibodi-antibodi 
monoklonal terhdadap pelbagai target antigen dengan berkesan. Oleh demikian, ini 
menyediakan penyelesaian yang menarik untuk penghasilan antibodi-antibodi 
manusia rekombinan. 
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DEVELOPMENT OF A NAÏVE HUMAN FAB ANTIBODY LIBRARY TO 
GENERATE MONOCLONAL ANTIBODIES AGAINST BmSXP 
RECOMBINANT ANTIGEN 
ABSTRACT 
Antibodies are glycoproteins produced by B-cells against molecules foreign to the 
body. This study focused on the production of antigen specific human The Fab 
region consists of one constant and one variable domain which are both located at the 
heavy chain and the light chain. An optimized protocol for the production of a 
recombinant Fab library of unimmunized donors from 3 major ethnic groups 
(Chinese, Malay and Indian) in Malaysia was carried out. We used peripheral blood 
lymphocytes total ribonucleic acids (RNA) from 90 donors to obtain variable genes 
(V-gene) specific cDNA. The Fab-encoding regions of IgM repertoire were 
individually amplified by polymerase chain reaction (PCR) using a diverse set of 
primers corresponding to the different variable region of the heavy (µ) and the light 
chains (к,λ). The diversity of the library is created via random combinatorial mixing 
of all heavy and light V-genes. A highly diverse naïve library is useful for the 
selection of antibodies against a panel of antigens. Phage selection was carried out 
against BmSXP using two different panning strategies to understand the efficiency of 
Fab library panning with different strategies. BmSXP is a recombinant antigen of 
Wuchereria Bancrofti which is specific for Bancroftian lymphatic filarial disease and 
is used for diagnostic of lymphatic filarial infection. The performance of both 
panning strategies suggests the difficulty for Fab library panning with an automated 
process as only the conventional panning method was able to isolate positive binders. 
Two monoclonal Fab antibodies against BmSXP were identified and confirmed. 
Although difficult, the production of a Fab naïve library is useful for the generation 
xxii 
  
of monoclonal Fab antibodies for downstream applications such as diagnostics. 
Phage display panning of a naïve Fab library is able to select monoclonal antibodies 
against the target antigens efficiently. This provides an attractive solution for the 
generation of recombinant human antibodies. 
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CHAPTER 1 
INTRODUCTION 
1.1 The Immune system  
The human immune system is a complex protection mechanism that involves several 
different cellular mechanisms. There are two natural mechanisms involved in 
fighting off infection and diseases in the human body, which are the innate and 
adaptive immune response (Kindt et al,. 2007). A major feature of the innate 
immunity is the ability to block the infiltration of infections by providing a physical 
barrier to wade off pathogens and ensure they never gain access into the host. This 
mechanism does not lead to any memory recognition of the antigens. On the other 
hand, the adaptive immune response is capable of specifically killing foreign 
microorganisms and differentiate self from non-self antigens. Unfortunately, 
pathogens use several strategies to escape elimination from the adaptive system for 
example by reducing its antigenicity, mimicking the host cell surfaces, selectively 
suppress the immune responses, and continual variation of antigen surfaces. The 
adaptive immunity provides a line of defense that eliminates a specific pathogen and 
generates a memory towards it whenever the body is invaded by the similar pathogen 
again. The natural cooperation between the innate and adaptive immune response in 
human provides a critical defense against organisms causing diseases, but such 
responses are not sufficient to completely protect a person from widespread 
infectious diseases (Janeway et al., 1999).  
1.2 Antibody development and its diversity. 
The human adaptive immune system has the capability to produce a highly diverse 
collection of antibody specificities due to the immunoglobulin genes encoded in the 
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germline. The maturation process is carried out by a gene assembly process that 
produces a collection of new genes through site-specific recombination. Variable 
region gene of the antibody consists of multiple germline segments that are classified 
as variable (V), diversity (D) and junction (J) segments.  
Human antibody variable heavy gene contains 48 VH, 23 D and 6 JH. The 
immunoglobulin (Ig) κ gene contains 41Vκ and 5 Jκ while Igλ contains 34 Vλ and 5 
Jλ (Kindt et al., 2007). These different segments are joined by recombination to 
produce a full antibody VDJ segment whereas light chain genes are able to undergo 
similar recombination excluding the D segment gene as outlined in figure 1.1. The 
random gene rearrangement of V-J and V-D-J combination contributes to the 
generation of a vast diversity of antibody repertoire (Lewis, 1994).  
A part of the antibody diversity also involves the pairing association between heavy 
and light chains. The combination of the associated heavy and light chain will lead to 
a higher complexity resulting in higher diversification of antibodies. Apart from that, 
antibody diversity is also associated by junctional flexibility caused by changes of 
amino acid at CDR3 of heavy and light chain. It is a process where nucleotides can 
either be lost or added (P / N –addition) during V-D-J and V-J rearrangements 
(Parslow, 2001). Antibody diversity could be generated in rearranged variable region 
gene units called somatic hypermutation after stimulation of B-lymphocyte by 
antigen encounter. As a result, nucleotides in VJ or VDJ units are substituted with 
alternatives and thus altering the specificity of the encoded antibodies further 
(Raaphorst et al., 1997). 
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Figure 1.1 Organization of immunoglobulin heavy chain gene segments 
rearrangement.  
  
 
 
 
 
 
 
 
 
4 
 
1.3 Antibody structure 
Antibodies are produced through secretion by plasma cells to act as the front line 
defense mechanism of our immune system. The common structure of an 
immunoglobulin molecule consists of four subunits that is made up of two heavy 
chain polypeptide chains held together by disulphide links and non-covalent 
interactions (Davies et al., 1990). Antibodies are heterodimers composed of 2 heavy 
chains and 2 light chains. There are two different light chains known as kappa (κ) 
and lambda (λ), either one of these will be associated with the heavy chain as one 
antibody, never both.  The light chain consists of only a variable domain (VL) and a 
constant domain (CL).  
The heavy chain is made up of a variable domain, either three or four constant 
domains juxtaposed to its variable domain (CH1, CH2, CH3 or CH4) and a hinge 
region depending on the antibody class (Kindt et al., 2007). The classes of the 
antibody are IgM, IgG, IgA, IgD, IgE or IgG where the heavy chain of each class 
will have either a κ or λ light chains. For IgG, IgA and IgD isotypes the constant 
domains involved are CH1, hinge, CH2 and CH3 while for IgM and IgE the domains 
are CH1, CH2, CH3 and CH4. Therefore, each class of antibody is determined by the 
proportion of heavy chain constant domain (Parslow, 2001).  
There are two significant parts of an antibody that is the antigen binding and effector 
functions located at the amino (N) - terminal and carboxyl (C) - terminal respectively 
Janeway et al. (1999). The general Y-structure is the same for all antibodies, 
however only the heavy and the light chain are responsible for recognizing antigens. 
The variability calculations (number of different amino acids at particular position / 
frequency of the most common amino acid at particular position), is able to show the 
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variation at the formation of the loop at the β-strand called the hypervariable region 
mostly known as complementary determining regions (CDRs) (Kindt et al., 2007). 
The remaining region with the least amount of variation is the framework (Fr) 
region. The variations among antibodies are located at the three CDRs that make up 
the binding site of the antigen epitope. It is this particular diversification that a lot of 
the antibodies are produced that can distinguish any protein target. These CDRs are 
separated by four relatively constant gene sequences as the framework (Janeway et 
al., 1999). Figure 1.2 shows the antibody Y-shaped structure and its ribbon drawing 
structure presentation.  
1.4 Phage display technology 
Antibodies are in high demand as they are suitable for diagnostic applications. 
Conventional methods for monoclonal antibody generation are lengthy and tedious 
(Li et al., 2006, Cambrosio and Keating, 1988). The introduction of phage display 
allowed for rapid generation of monoclonal antibodies (Willats, 2002). The method 
is based on a bacteriophage that is harmless to humans but only infects bacteria as a 
reproduction host. The viral genomic material is able to enter the bacteria host cell 
and directs the production of progeny phage. The progeny phage would infect other 
bacteria cells and secrete a new phage in the cytoplasm of the cell. However, a 
filamentous phage assembles its progeny on the cell surface by a special secretory 
mechanism and leaves the cell viable for the next round of infection (Marvin, 1998). 
It has been reported that the insertion of a foreign DNA into the phage genome is 
capable of yielding a phage particle with the foreign peptide sequence displayed on 
the phage coat protein (Smith, 1985). By exploiting the morphology and secretory 
mechanism of the filamentous phage, it is possible to physically link genotype and 
phenotype together (Barbas et al., 2004). Therefore, DNA sequence encoding 
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Figure 1.2 Typical structure of an antibody molecule. A) Antibody consists of two 
heavy chains and two light chains which are linked together by disulphide bonds. 
One bond linked together VH and VL, two bonds linked two VHs and several bonds 
linking antibody subdomains. B) Finger-like loops of a single light chain whereby 
binding of antigen occur. Figure adapted from (Alberts et al., 2013). 
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the foreign molecules can be retrieved through DNA sequencing as first reported by 
George Smith in 1985 leading to the innovation of phage display technology.  
1.4.1 Structure of bacteriophage  
Filamentous bacteriophage belongs to a type of related viruses that contains single-
stranded viral DNA that infects only gram-negative bacteria. It is 2000 nm in length 
and 6-10 nm in diameter enclosing all viral DNA genome consisting of 11 genes 
(Zimmermann et al., 1986). The functions of the 11 genes are: p (III, VI – IX) for 
coat proteins, p (I , IV and XI) for phage assembly, p (II and X) for DNA replication 
and lastly pV for binding ssDNA. The viral mass consists mainly of about 2700 
copies of the pVIII major coat protein, about 3-5 copies of pVII and pIX at one side 
which are assembled first and 3-5 copies of pIII and pVI on the other side are for 
phage particle stability and infection (Russel et al., 1997). Figure 1.3 shows the basic 
filamentous phage particle consisting of its major coat proteins. 
1.4.2 Infection mechanism  
Filamentous phage is dependent on the F-pilus for infection and it does not kill its 
host (Marvin, 1998). The pIII minor coat protein consists of three domains which are 
carboxyl terminal (C), amino terminal 2 (N2) and amino terminal 1(N1) which are 
separated by a glycine-rich linker region (Deng et al., 1999). Initially, the N2 domain 
of the phage particle binds strongly with the F-pilus of E.coli and mediate the 
binding of the N1 domain to the bacteria protein TolA (Click and Webster, 1997). By 
natural forces, it pulls the phage particle closer to the bacteria. Consequently, the N1 
domain is released from the N1N2 complex of the pIII after the F-pilus binding. 
Next, free N1 domain will interact with TolA receptor (Karlsson et al., 2003). TolA 
is a membrane bound protein which was believed to incorporate other membrane  
8 
 
 
 
Figure 1.3 A representation of filamentous phage particle. The major coat proteins 
of the filamentous phage such as M13KO7 ; pIII, pVI, pVII, pVIII and pIX.  
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proteins, TolQ and TolR to form a complex (Click and Webster, 1997). This protein 
complex facilitates the pIII and pVIII into the cytoplasmic region of the bacteria. 
Finally, anchored TolA at the cytoplasm will enter the periplasm where phage 
infection occurrs. At this point, the viral ssDNA is secreted into the cytoplasm and 
gets replicated into dsDNA format; making it ready for the expression of the coat 
proteins. The new phage particles are assembled and will be secreted into the 
medium (Rakonjac et al., 1999). Figure 1.4 shows the infection mechanism of the 
filamentous phage. 
1.4.3 Display formats 
There are two commonly used coat protein for phage display which is pVIII and pIII 
(Smith and Petrenko, 1997). The major coat protein, pVIII exist in thousands of 
copies that make up the long cylindrical phage particle while pIII consists of three 
functional domains (Webster, 1996). The presentation of any foreign sequence is 
usually inserted at the C - terminus of the pVIII and pIII coding sequences while the 
linker sequences are inserted at the N - terminus on a phagemid vector. Protein pVIII 
only allows short peptides (6 - 8 residues) to be displayed on it as it could interrupt 
the interactions of the pVIII molecules during assembly (Qi et al., 2012). However, 
there are reports on the fusion of antibody fragments on pVIII (Kang et al, 
McCafferty et al). On the other hand, pIII coat proteins are able to tolerate large 
foreign molecules on it and its infectivity still remained active. This makes pIII the 
ideal coat protein for the presentation of foreign proteins for display.  
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Figure 1.4 The mechanism of bacterial infection by filamentous phage. First, the pIII 
coat protein N2 domain interacts with the bacterial F-pilus followed by recognition 
of N1 domain with TolA. Next, retraction of the F-pilus brings the phage closer and 
opening of the phage head to release phage DNA. Figure adapted from (Karlsson et 
al., 2003) 
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1.4.4 Antibody libraries by phage display  
Phage display has become a powerful technology that allows for in vitro mimicking 
of the natural human production of antibodies in vivo. Fully human monoclonal 
antibodies (mAbs) production is efficient for downstream application for humans due 
to the highe risk associated with the use of murine derived mAbs (Vaughan et al., 
1998). Phage display is a robust scientific research and development for antibody 
selection.  
1.4.4.1 Recombinant antibody libraries  
There are four types of antibody libraries that can be generated for scientific 
applications depending on the source of the antibody genes obtained; naïve (non-
immunized), immunized, semi-synthetic and fully synthetic library (Ponsel et al., 
2011, Marks and Marks, 1996). Libraries derived from immunized and non-
immunized individuals are directly influenced by the natural human antibody gene 
diversity while semi-synthetic and synthetically design libraries are based on the 
designed gene to exhibit similar diversities found in natural human antibody 
repertoires. 
Naïve libraries can be built using peripheral blood or bone marrow of healthy 
individuals. These libraries are used to harvest the natural binding sites of the 
antibodies (Løset et al., 2005). The antibody repertoire is constructed from natural 
rearranged V-genes of the B-cells representing in vivo IgM antibodies that are 
commonly produced by developing B-cells that do not show any preference to any 
particular antigen that provides higher percentage of success when isolating new 
binders. 
12 
 
 Immunized antibody libraries are made using genetic materials from individuals that 
have contracted or have been exposed to a particular disease (de Carvalho Nicacio et 
al., 2002). This will skew the antibody producing cells to generate antibodies against 
immunogenic antigens related to the disease. This can prove to be useful to generate 
high affinity and specific antibodies against antigens of that particular disease. 
Therefore the preferred antibody gene isotype for immunized libraries is usually IgG. 
The synthetic antibody libraries are made up of antibody gene variation that can be 
designed and generated through degenerate oligonucleotides to produce fully 
synthetic heavy and light chains with different properties. The entire gene fragment 
of a synthetic antibody is chemically synthesized in vitro (Knappik et al., 2000). 
Such libraries allow massive customization in terms of framework preferences and 
even CDR designs. As the randomization in such libraries generates highly diverse 
repertoires, the library will have the tendency to exhibit unskewed repertoire much 
like those of the naïve libraries. Semi-synthetic libraries are a fusion of the naïve and 
synthetic library designs (De Kruif et al., 1995). This is because in semi-synthetic 
libraries, the genetic information can be obtained from donors and the randomized 
regions or framework regions can be synthesized. This allows semi-synthetic 
antibody libraries to present a naïve repertoire too. Therefore semi- and fully 
synthetic libraries can function to generate antibodies against any antigen target. 
Figure 1.5 shows the four different types of antibody libraries can be generated for 
phage display.  
1.5 Selection process (Bio-panning) 
A heterogeneous mixture of the phage clones or phage library is produced with 
standard molecular biology techniques involving the exploitation of DNA vectors to 
accommodate V-gene inserts and accommodate packaging to mature phage particles 
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by appropriate E.coli hosts (Galanis et al., 1997) . In order for the antibody to be 
presented on the phage particle, the V-genes need to be tethered to the phage coat 
protein so that the presentation will be a fusion of both proteins. The integrity of the 
antibody presented is maintained as it is physically placed on the surface of the 
phage particle. This physical interaction between the antibody and phage particle 
allows for easy in-vitro selection of specific antibodies against immobilized target 
antigens (Romanov, 2003). This selection process is commonly known as bio-
panning. The selection process is a collection of repetitive rounds that allows 
antibody displaying phages to bind immobilized antigens on solid phases. The 
antigens can be immobilized onto (1) plastic tubes (Marks et al., 1991), (2) columns 
with target-activated matrix (McCafferty et al., 1990), (3) biotinylated antigens 
selection (Hawkins et al., 1992), (4) an automated selection whereby the antigens are 
coated on the magnetic particles (Konthur and Walter, 2002), (5) immunopins (Lou 
et al., 2001) and (6) microtitre plate (Krebs et al., 2001). Each solid phase provides a 
different set of advantages and disadvantages. The choice of the best suitable solid 
phase is mainly dependent on the target antigen and selection conditions. During the 
panning process, a repetitive cycle of physical binding and removal of unwanted 
phage particles is carried out. The initial binding step allows for specific binders to 
capture the target antigens and interact with it in a suitable environment. The wash 
steps are introduced to remove unbound phages and contaminants (Goodchild et al., 
2005). The panning process can be customized to allow for different stringency. This 
will affect the end product of the panning whereby antibody selectivity can be tuned 
with different competing conditions. The antibody bound to the target can be eluted 
using several different techniques such as acid/basic elution (Hoogenboom et al., 
1998, Marks et al., 1991), enzymatic cleavage (Ward et al., 1996) or reducing agents  
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Figure 1.5 Antibody libraries type A) Generation of naïve libraries are from the B-
cells isolation of non-immunized donor. B) Generation of immunized libraries are 
from the B-cells isolation of non-immunized donor. C) Generation of synthetic 
libraries are fully based on the computational design of the gene sequence D) 
Generation of semi- synthetic libraries are combination of pre-designed segments 
and natural source of gene sequence. Figure adapted from (Ponsel et al., 2011). 
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(Kretzschmar and von Rüden, 2002). The rescued phage clones are then infected 
with E.coli allowing the selected phage to be amplified as input phage for the next 
round of panning (Goodchild et al., 2005). To identify monoclonal binders, single 
clones have to be picked from a pool of enriched binders and analyzed individually. 
Figure 1.6 shows the bio-panning process by phage display technology. 
1.6 Applications of recombinant antibody 
The main characteristic for the antibodies to be useful for various applications is 
dependent on the high affinity and specificity towards an antigen. In 1975, Köhler 
and Milstein (Köhler and Milstein, 1975) reported the revolutionary method to 
generate antibodies by fusing murine antibody-producing cells with myelomas from 
bone marrow to produce hybridomas. Hybridoma technology has been applied 
successfully to produce monoclonal antibodies against many antigens. The method 
involves the isolation of hybridomas producing antibodies against the selected 
antigen by screening each individual hyridoma (Cambrosio and Keating, 1992). One 
major complication associated with hyridoma-based antibodies is the potential 
allergic reaction accustomed to the application of animal derived antibodies in 
humans. The allergic reaction is a result of the human immune system reacting 
against the foreign animal derived antibody as a potential threat (Khazaeli et al., 
1994). Therefore, antibodies derived using hybridoma technology was not able to 
achieve its intended benefits. Therefore, to circumvent this issue various 
modifications have been introduced. The modifications lead to the introduction of 
chimeric, humanized and ultimately fully human antibodies. Another major 
consideration for recombinant antibodies is the ability to increase production with 
microbial expression systems. For example, Escherichia coli (E.coli) as an 
expression host has become a widely used technique that is able to produce  
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Figure 1.6 A scheme of bio-panning strategy by phage display. In phage display 
panning where antibodies are presented on the phage particles and add into 
immobilized target antigens for binders. This is followed by several wash steps to 
remove unbound phages and elution and propagation of the bounded phages. Figure 
adapted from (Goodchild et al., 2005). 
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monoclonal antibodies due to its fast growth rate, the ability to accept a vector 
carrying specific genetic material and a high transformation rate (Plückthun, 1992). 
The production of full-length antibody is relatively difficult by expression in the 
E.coli system if compared to the expression of smaller antibody fragments (Simmons 
et al., 2002). For instance, the first antibody produced is the fragment variable (Fv) 
domain antibodies which comprises of either the VH or VL domains expressed in the 
periplasmic environment of the bacterial cells (Skerra and Pluckthun, 1988). As the 
binding characteristics of an antibody is associated to the ability of both the heavy 
and light chain domains to work in tandem, a modified fragment namely the single 
chain Fragment variable (scFv) was introduced. scFv fragments consist of both 
variable domains to be expressed as one fragment with the help of a peptide linker 
(Bird et al., 1988). Even so, variations in the length of the linker sequence have been 
reported to promote aggregation during expression (Whitlow et al., 1993).  
On the other hand, the stabilization of Fab molecules is generally associated to the 
disulphide bond between the variable heavy and the light chain. The production of 
Fab molecules requires the transportation of the Fab to the periplasmic space for 
disulphide bond formation. However, expression levels of Fab are difficult due to the 
need for both fragments to be independently expressed and form a disulfide bond in 
the periplasmic space (Skerra and Plückthun, 1991). However, Fab molecules are 
important fragments for antibody engineering. This is because Fab fragments are 
suitable for direct transfiguration to the larger full immunoglobulin molecule without 
the loss of binding efficiency (Rader, 2009). This would make full antibody molecule 
production easier and more efficient. Figure 1.7 shows the different recombinant 
antibody formats for phage display. 
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Figure 1.7 Schematic representation of different antibody formats. Fv (fragment 
variable) comprises of VH and VL. scFV (single chain fragment variable) is included 
of VH and VL connected by a linker. Fab (fragment antigen binding) comprises of 
VH and VL with a constant region (CH1 and CL respectively) connected by a 
disulphide linkage. scFab (single chain fragment antigen binding) consists of Fab but 
with a linker connection. 
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1.6.1 Application of Fab fragments  
The developments in antibody generation technology have enabled recombinant 
antibodies to be made fully of human fragment (Yan and Xu, 2006, Barbas et al., 
2004). The most widely used recombinant antibodies with respect to the antigen 
binding fragments are the scFV and Fab. Both recombinants are biologically and 
physically different in properties. Fab in general has a better stability comparison. 
The interaction of the HC and LC by an interchain disulfide bond is the major 
contribution towards the stability of a Fab fragment (Röthlisberger et al., 2005) . 
Apart from that, a synergy between the VH, VL, CH1 and CL domains had shown 
significant stabilization effects within the interfaces by the intrachain disulfide 
bonding. These were reported by Shimba et al. which discussed Fab stability in 
comparison to Fv based on thermodynamics study (Shimba et al., 1995). Another 
study by Daniela Röthlisberger et al. discussed the stabilizing effects of Fab domain 
interactions and compared that with the scFv. The Fab domain showed several key 
advantages such as better mutual stabilization of both HC and LC, better stability due 
to the presence of the interchain disulfide bond producing and kinetic stabilization 
(Röthlisberger et al., 2005). As such the application of Fab monoclonal antibodies 
are still used due to the wide benefits it is able to provide in terms of format 
conversion even with the challenges posed in handling. 
1.7 Model Target – BmSXP Recombinant Antigen 
In this work, the model antigen selected was BmSXP antigen used for detection of 
bancroftian filariasis. It is a recombinant protein of Wuchereria Bancrofti - a filarial 
nematode that lives in the human lymphatic system. BmSXP is a highly specific 
recombinant antigen used for the detection of specific IgG4 antibodies for 
bancroftian worms (Khoo et al., 2010). BmSXP recombinant protein was an ORF of 
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SXP1 gene from Brugia Malayi cDNA library which its sensitivity is 95% in 
detection of bancroftian filariasis infection. The used of this recombinant antigen 
with BmR1 recombinant antigen (specific for brugian filariasis detection) was found 
to enhance the specificity and sensitivity of lymphatic filariasis for diagnostic 
purposes. (Ab Rahman, 2008) Therefore, there is a necessity to produce antibodies 
against it for future downstream applications, mainly for immunopurification. A 
common challenge in the production of the diagnostic kit is the purification of the 
antigen with high specificity. As the current diagnostic kit is based on antibody 
detection, the generation of monoclonal antibodies could also pave the way for the 
development of an antigen detection system.  
1.8 Statement of problem and rationale of study 
The antibody molecule is an integral part of many proteomics, diagnostic and 
therapeutic research due to its ability to specifically bind a target antigen. Production 
of human antibodies has been explored widely in a race to find unique binders. In 
vitro antibody production through phage display technology is an interesting 
alternative to conventional methods for antibody development. Phage display allows 
for a faster and easier approach to generate antibodies with the generation of an 
antibody library mimicking the natural antibody diversity. Antibody variable regions 
(variable heavy chain/variable light chain) are easily manipulated and displayed on 
the phage particle. In order to develop this technology in-house to overcome the 
complications of antibody production, a naïve Fab library was developed and used to 
identify monoclonal antibodies against BmSXP. Fab antibody still possess a lot of 
challenges as a tool for detection of diagnostic and therapeutic studies by 
development of phage display technology. Bypassing the use of animals, phage 
display is a well-established technology for antibody isolations of fully human small 
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antibody format such as scFV and Fab. Generation of Fab antibody by this 
technology was a challenge due to two significant reasons. First, Fab fragment is 
larger compare to scFv fragment to be expressed in E.coli system. Second, the 
presentations of the Fab on the phage particle was a synergy between two 
independent chains endeavoring for each other in E.coli periplasm which always 
leading to low yield of phage presenting full Fab fragment. Therefore, the generation 
of a highly diverse naive Fab library for phage display was indeed required to 
produce quality Fab antibodies.  
1.9 Research Objectives 
1. To generate a naïve fragment antigen- binding library (Fab fragment library) 
2. To produce human monoclonal Fab antibodies by phage display against BmSXP 
recombinant antigen 
3. To evaluate the specificity of the monoclonal antibodies generated 
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CHAPTER 2 
MATERIALS AND METHODOLOGIES 
2.1 Materials for blood collection and isolation of B – lymphocytes 
2.1.1 Blood samples 
90 donors (Malay, Chinese and Indian) 
2.1.2 Related materials 
K2 EDTA Blood collection tubes 3.0 mL                             BD Vacutainer , USA 
Ficoll – Paque TM PLUS                                                        GE Healthcare Life 
Sciences , UK 
β – Mercaptoethanol (β-ME)                                                Sigma Aldrich, USA 
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2.2 Materials for molecular biology work 
2.2.1 Enzymes and corresponding buffers 
NcoI NEB3/BSA New England Biolabs, 
USA 
MluI NEB3/BSA New England Biolabs, 
USA 
SalI HF NEB4/BSA New England Biolabs, 
USA 
NheI HF NEB4/BSA New England Biolabs, 
USA 
Pfu DNA 
polymerase 
10X Pfu Buffer (MgSO4) Thermo Scientific, USA 
Vent DNA 
Polymerase 
10X ThermoPol buffer New England Biolabs, 
USA 
T4 DNA Ligase T4 DNA ligase buffer New England Biolabs, 
USA 
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2.2.2 Bacterial strains and phages 
 
 
 
 
 
 
DH10B T1 
Phage 
Resistant 
Cells 
F
-
mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15 
ΔlacX74 recA1 endA1araD139Δ 
(ara, leu)7697 galU galK λ-
rpsL nupG tonA 
Invitrogen, 
Carlsbad, 
USA 
TG1  
 
supE thi-1 ∆(lac-proAB) ∆(mcrB-
hsdSM)5 (rK–mK–) [F´ traD36 proAB 
lacIqZ∆M15] 
 
Agilent 
Technologies, 
USA 
XL1 Blue  
recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´ proAB lacIqZ∆M15 
Tn10 (Tetr)] 
Agilent 
Technologies, 
USA 
M13KO7 
helper 
phage 
kn
r
 
New England 
Biolabs, USA 
